Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/42925
OF DRUGS AND TRYPANOSOMATIDS: NEW TOOLS AND KNOWLEDGE TO REDUCE BOTTLENECKS IN DRUG DISCOVERY
neglected tropical diseases
Leishmania
Trypanosoma cruzi
Trypanosoma brucei
drug discovery
in vitro models
in vivo models
genomics
drug resistance
Autor(es)
Afiliação
Adamas University
Université de Montréal
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil
Université de Montréal
Université de Montréal
Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil
Université de Montréal
Resumo em Inglês
Leishmaniasis (Leishmania species), sleeping sickness (Trypanosoma brucei), and Chagas disease (Trypanosoma cruzi) are devastating and globally spread diseases caused by trypanosomatid parasites. At present, drugs for treating trypanosomatid diseases are far from ideal due to host toxicity, elevated cost, limited access, and increasing rates of drug resistance. Technological advances in parasitology, chemistry, and genomics have unlocked new possibilities for novel drug concepts and compound screening technologies that were previously inaccessible. In this perspective, we discuss current models used in drug-discovery cascades targeting trypanosomatids (from in vitro to in vivo approaches), their use and limitations in a biological context, as well as different examples of recently discovered lead compounds.
Palavras-chave em inglês
trypanosomatidsneglected tropical diseases
Leishmania
Trypanosoma cruzi
Trypanosoma brucei
drug discovery
in vitro models
in vivo models
genomics
drug resistance
Compartilhar